OVERALL SURVIVAL (OS) AND PROGRESSION FREE SURVIVAL (PFS) RESULTS FOR A RANDOMIZED PHASE 2 TRIAL OF IPILIMUMAB (IPI) AND PACLITAXEL/CARBOPLATIN (P/C) IN FIRST-LINE STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Lynch, T. J., Jr. [1 ]
Neal, J. [2 ]
Bondarenko, I. [3 ]
Luft, A. [4 ]
Serwatowski, P. [5 ]
Barlesi, F. [9 ]
Chacko, R. [10 ]
Sebastian, M. [6 ]
Cuillerot, J. [7 ]
Reck, M. [8 ]
机构：
[1] Yale Univ, Ctr Canc, New Haven, CT USA
[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
[3] Dnipropetrovsk Municipal Clin Hosp 4, Dept Oncol Radiodiagnosis & Radioth, Dnepropetrovsk, Ukraine
[4] Leningrad Reg Clin Hosp, State Inst, St Petersburg, Russia
[5] Oddzial Chemioterapii, Szczecin, Poland
[6] Johannes Gutenberg Univ Mainz, Mainz, Germany
[7] Bristol Myers Squibb Co, Global Clin Res, Wallingford, CT 06492 USA
[8] Hosp Grosshansdorf, Grosshansdorf, Germany
[9] Univ Mediterranee Assistance Publ Hapitaux Marsei, Marseille, France
[10] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：126 / 126
页数：1
相关论文
共 50 条
  • [31] Preliminary results of a randomized phase II trial of pemetrexed (P) plus carboplatin (Cb) ± enzastaurin (ENZ) versus docetaxel (D) plus Cb as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer (NSCLC)
    Kocs, D. M.
    Raju, R. N.
    Socinski, M. A.
    Stinchcombe, T. E.
    Rousey, S. R.
    Barrera, D.
    Wang, Y.
    Bromund, J.
    Treat, J.
    Obasaju, C. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Influence of crossover therapy on the association between progression-free survival (PFS) and overall survival (OS) in randomized trials of molecular-targeted agents for advanced non-small cell lung cancer (NSCLC).
    Hotta, K.
    Kiura, K.
    Suzuki, E.
    Takigawa, N.
    Fujiwara, Y.
    Ichihara, E.
    Tabata, M.
    Tanimoto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] FINAL OVERALL SURVIVAL (OS) RESULTS FROM A PHASE III, RANDOMISED, OPEN-LABEL, FIRST-LINE STUDY OF GEFITINIB (G) V CARBOPLATIN/PACLITAXEL (C/P) IN CLINICALLY SELECTED PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ASIA (IPASS)
    Yang, C-H.
    Fukuoka, M.
    Mok, T. S.
    Wu, Y-L.
    Thongprasert, S.
    Saijo, N.
    Chu, D-T.
    Jiang, H.
    Duffield, E. L.
    Ichinose, Y.
    ANNALS OF ONCOLOGY, 2010, 21 : 1 - 2
  • [34] A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) non-small cell lung cancer (NSCLC): Update of the Alpha Oncology trial (A1-99002L).
    Treat, J
    Belani, CP
    Edelman, MJ
    Socinski, MA
    Ansari, RH
    Obasaju, CK
    Bloss, JD
    Marinucci, DM
    Catalano, RB
    Comis, RL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1096S - 1096S
  • [35] A randomized phase II trial comparing pulsed erlotinib before or after carboplatin and paclitaxel in patients with stage IIIB or IV non-small cell lung cancer
    Riely, G. J.
    Rudin, C. M.
    Kris, M. G.
    Senturk, E.
    Azzoli, C. G.
    Brahmer, J.
    Fogle, M.
    Ginsberg, M.
    Miller, V. A.
    Rizvi, N. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Phase II trial of satraplatin (S) and paclitaxel (P) in first-line advanced non-small cell lung cancer (NSCLC) treatment: Final results
    Thompson, D. S.
    Spigel, D. R.
    Hainsworth, J. D.
    Jones, S. F.
    Burris, H. A., III
    Sade, L.
    Raefsky, E.
    Greco, F. A.
    Yun, S.
    Noursalehi, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [37] Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations
    Inoue, A.
    Kobayashi, K.
    Maemondo, M.
    Sugawara, S.
    Oizumi, S.
    Isobe, H.
    Gemma, A.
    Saijo, Y.
    Yoshizawa, H.
    Morita, S.
    Hagiwara, K.
    Nukiwa, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] Disease-free survival (DFS) as a predictor of overall survival (OS) in completely resected early stage non-small cell lung cancer (NSCLC)
    West, H.
    Hu, X.
    Burke, T.
    Walker, M. S.
    Wang, Y.
    Samkari, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S74 - S75
  • [39] Final results of a randomized phase II trial of pemetrexed (P) plus carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) plus Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)
    Stinchcombe, Tom
    Raju, Robert N.
    Couch, Linda S.
    Kocs, Darren M.
    Jotte, Robert
    Wang Yunfei
    Bromund, Jane
    Marciniak, Martin D.
    Treat, Joseph
    Obasaju, Coleman K.
    Socinski, Mark
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S383 - S384
  • [40] Final results of a randomized phase II trial of pemetrexed (P) plus carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) plus Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)
    Obasaju, C. K.
    Raju, R. N.
    Stinchcombe, T.
    Couch, L. S.
    Jotte, R.
    Kocs, D. M.
    Wang, Y.
    Bromund, J.
    Treat, J.
    Socinski, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345